Evogene Set to Showcase Key Pharma Innovations at BIO-Europe Spring 2026

Evogene's Presentation at BIO-Europe Spring 2026

Evogene Ltd., a leader in computational chemistry and the innovative design of small molecules, is slated to share its remarkable advancements at the BIO-Europe Spring 2026 conference. This prominent event will take place from March 23 to 25 in Lisbon, Portugal. The company, which focuses on applying generative AI technology to both pharmaceutical and agricultural sectors, has positioned itself as an influential player in drug discovery, and this conference provides an excellent platform to showcase its achievements.

Dr. Gabi Tarcic, Chief Development Officer, and Dr. Olga Nissan, Vice President of Business Development, will represent Evogene at the conference. Dr. Nissan is scheduled to deliver a significant presentation focused on Evogene's latest technological innovations in small-molecule discovery facilitated by its proprietary platform, ChemPass AI™. This advanced system is designed to explore extensive chemical spaces, yielding unique and highly effective molecules that are optimized for various critical parameters.

ChemPass AI™: A Game Changer in Drug Discovery

The introduction of ChemPass AI™ marks a pivotal shift in how pharmaceutical companies approach drug development. Through integrating AI-driven molecular design with experimental validation, Evogene has created a method that drastically enhances the probability of success in drug discovery. The technology allows for collaborative opportunities with various pharmaceutical and biotech partners, which highlights the company's strategic vision of combining scientific innovation with practical industry needs.

At the BIO-Europe event, the sharing of detailed insights related to AI-driven breakthroughs in drug development aims to stimulate further partnerships and enhance collaborations within the pharmaceutical community. Attendees interested in more personalized discussions can request one-on-one meetings with Dr. Tarcic or Dr. Nissan during the conference.

Invitation to Attend

For those interested in attending, registration is available through the BIO-Europe Spring website. Evogene’s team encourages active participation and engagement with attendees who can benefit from discussions around cutting-edge innovations in pharmaceutical technology.

About Evogene Ltd.

Based in Rehovot, Israel, Evogene Ltd. is distinguished as a pioneer in computational chemistry. The firm specializes in the generative design of small molecules geared towards the pharmaceutical and agricultural industries. Their goal is to enhance the discovery process while also ensuring that derived products align closely with real-world demands.

As Evogene continues to innovate, their presence at significant industry conferences underscores their commitment to advancing pharmaceutical technologies and fostering growth through strategic partnerships. The insights shared at BIO-Europe Spring 2026 are expected not only to inform but also to inspire ongoing discussions about the future of drug discovery and the role of AI in transforming this landscape.

By engaging in this global conference, Evogene Ltd. continues to assert its position at the forefront of pharmaceutical innovation, paving the way for future breakthroughs in drug development.